Axovant Gene Therapies Ltd (NASDAQ:AXGT) shot up 8.1% during trading on Wednesday . The company traded as high as $4.88 and last traded at $4.83, 227,900 shares were traded during trading. A decline of 32% from the average session volume of 335,259 shares. The stock had previously closed at $4.47.
A number of equities research analysts recently weighed in on AXGT shares. Robert W. Baird raised Axovant Gene Therapies from a “neutral” rating to an “outperform” rating and dropped their price target for the company from $16.00 to $13.00 in a report on Monday, August 12th. ValuEngine raised Axovant Gene Therapies from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded Axovant Gene Therapies from a “hold” rating to a “strong-buy” rating and set a $6.00 target price on the stock in a report on Wednesday, November 13th. Finally, Chardan Capital raised their target price on Axovant Gene Therapies from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, October 28th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $24.72.
The stock’s 50 day simple moving average is $5.79 and its two-hundred day simple moving average is $6.38. The company has a market capitalization of $107.12 million, a P/E ratio of -0.60 and a beta of 1.24. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.41 and a quick ratio of 1.41.
About Axovant Gene Therapies (NASDAQ:AXGT)
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
See Also: How the Dogs of the Dow Strategy Works
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.